Update of the single-arm phase II L-MIND study of MOR208 (Tafasitamab) + lenalidomide (LEN) in relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL): High overall response rates (ORR) achieved in patient subgroups with poor prognosis

André, Marc;André, Marc;et.al.
(2019) 2019 ASCO Annual Meeting — Location: McCormick Place, Chicago (USA) (31.May.2019)

Files

MAndré-PosterASCO-Chicago2019.pdf
  • Open Access
  • Adobe PDF
  • 212.96 KB
Download

Details

Authors
  • André, MarcThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
    Author
  • André, MarcUCLouvain
    Author
  • et. al.
Abstract
CD19 is broadly and homogeneously expressed across different B-cell malignancies including DLBCL, and enhances B-cell receptor (BCR) signaling and tumor cell proliferation.1,2 MOR208 (Tafasitamab) is an Fc-enhanced, humanized, monoclonal antibody that targets CD19 on tumor cells leading to natural killer (NK) cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC), macrophage-mediated antibody-dependent cellmediated phagocytosis (ADCP) and direct cytotoxicity.LEN is an immunomodulatory drug [IMiD®], and has both antiproliferative and antiangiogenic properties, and stimulates the activity of effector cells such as NK cells.5 • Both MOR208 and LEN have demonstrated single agent activity in patients with R-RDLBCL.4,6 • Encouraging activity has been recently reported from the MOR208 + LEN combination (preliminary results, Salles et al, ASH 2018).
Affiliations

Citations

  • APA
  • Chicago
  • FWB

André, M., André, M., & et al. (2019). Update of the single-arm phase II L-MIND study of MOR208 (Tafasitamab) + lenalidomide (LEN) in relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL): High overall response rates (ORR) achieved in patient subgroups with poor prognosis. 2019 ASCO Annual Meeting, McCormick Place, Chicago (USA). https://hdl.handle.net/2078.5/62967